FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
Status: Acquired
Dimension Therapeutics
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics went public in 2015 (NASDAQ: DMTX). The company has since been acquired by Ultragenyx Pharmaceuticals and is no longer a publicly traded company.
CardioKine
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.
Bikam Pharmaceuticals
Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.
Acacia Pharma
Acacia Pharma (EURONEXT: ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia developed BARHEMSYS to marketing approval and was acquired by Eagle Pharmaceuticals in 2022.